Darius Lakdawalla

Darius Lakdawalla's AcademicInfluence.com Rankings

Darius Lakdawalla

Economics

#2484

World Rank

#2837

Historical Rank

#893

USA Rank

Microeconomics

#173

World Rank

#182

Historical Rank

#56

USA Rank

economics Degrees

Download Badge

Economics

Darius Lakdawalla's Degrees

PhD Economics University of Chicago
Bachelors Economics University of California, Berkeley

Similar Degrees You Can Earn

Best Online Bachelor's of Economics for 2024

Why Is Darius Lakdawalla Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Darius Lakdawalla is an economist. He is the Quintiles Chair in Pharmaceutical Development and Regulatory Innovation at the School of Pharmacy at the Leonard D. Schaeffer Center for Health Policy and Economics at the University of Southern California and co-founder and Chief Scientific Officer of Precision Health Economics, a health care consulting firm. Dr. Lakdawalla also serves as the Executive Director of the "Innovation and Value Initiative" , a multi-stakeholder scientific initiative that aims to improve the way value is measured and rewarded in the healthcare marketplace.

(See a Problem?)

Darius Lakdawalla's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Malpractice risk according to physician specialty. (2011) (750)
The growth of obesity and technological change. (2009) (364)
Are the Young Becoming More Disabled? (2001) (284)
Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3]. (2018) (253)
Welfare-Enhancing Technological Change and the Growth of Obesity. (2005) (239)
The health and cost consequences of obesity among the future elderly. (2005) (199)
Impact of oral nutritional supplementation on hospital outcomes. (2013) (191)
The nonprofit sector and industry performance (2006) (190)
Consequences of health trends and medical innovation for the future elderly. (2005) (182)
HIV Breakthroughs and Risk Sexual Behavior (2004) (157)
Burden of illness of diabetic macular edema: literature review (2010) (147)
HOW DOES TERRORISM RISK VARY ACROSS SPACE AND TIME? AN ANALYSIS BASED ON THE ISRAELI EXPERIENCE (2006) (123)
Labor Supply and Weight (2007) (120)
On average, physicians spend nearly 11 percent of their 40-year careers with an open, unresolved malpractice claim. (2013) (103)
Nonprofit Production and Competition (1998) (100)
A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7]. (2018) (100)
How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies. (2012) (98)
The Rise in Old Age Longevity and the Market for Long-Term Care (1998) (96)
Economic instruments for obesity prevention: results of a scoping review and modified delphi survey (2011) (92)
A Theory of Health Disparities and Medical Technology (2005) (88)
Outcomes of medical malpractice litigation against US physicians. (2012) (84)
Understanding Health Disparities Across Education Groups (2001) (79)
An Economic Evaluation of the War on Cancer (2009) (78)
Chronic Disease and Severe Disability Among Working-Age Populations (2008) (78)
The effect of regulation on pharmaceutical revenues: experience in nineteen countries. (2008) (77)
Sexually Transmitted Diseases Among Users of Erectile Dysfunction Drugs: Analysis of Claims Data (2010) (75)
Catastrophe Bonds, Reinsurance, and the Optimal Collateralization of Risk Transfer (2006) (73)
Food Prices and the Dynamics of Body Weight (2009) (71)
Innovation and The Welfare Effects of Public Drug Insurance. (2009) (70)
An analysis of whether higher health care spending in the United States versus Europe is 'worth it' in the case of cancer. (2012) (68)
The Declining Quality of Teachers (2001) (68)
The Insurance Value of Medical Innovation (2014) (67)
Economics of the Pharmaceutical Industry (2018) (66)
Economic burden of community-based disease-associated malnutrition in the United States. (2014) (66)
The Welfare Effects of Medical Malpractice Liability (2009) (65)
Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China (2016) (63)
Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework. (2017) (60)
Disability Forecasts and Future Medicare Costs (2004) (60)
Effect of hospital use of oral nutritional supplementation on length of stay, hospital cost, and 30-day readmissions among Medicare patients with COPD. (2015) (60)
Forecasting the Nursing Home Population (2003) (59)
The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment. (2012) (57)
Geographic Variation in Health Care: The Role of Private Markets (2010) (56)
How Does Health Insurance Affect Workers Compensation Filing? (2007) (55)
Approaches to Aggregation and Decision Making—A Health Economics Approach: An ISPOR Special Task Force Report [5]☆ (2018) (54)
Does Medicare benefit the poor (2006) (53)
The value of specialty oncology drugs. (2010) (52)
Determinants of Direct Foreign Investment and Its Connection to Trade (1994) (52)
U.S. pharmaceutical policy in a global marketplace. (2008) (51)
Differences in health between Americans and Western Europeans: Effects on longevity and public finance. (2011) (50)
Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA. (2010) (45)
The Economics of Teacher Quality* (2006) (45)
Health Insurance as a Two-Part Pricing Contract (2006) (44)
Lifetime Economic Burden of Crohn's Disease and Ulcerative Colitis by Age at Diagnosis. (2020) (42)
Technological Change and the Growth of Obesity (2002) (37)
Obesity and Disability: The Shape of Things to Come (2007) (36)
Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with Schizophrenia. (2016) (35)
Are investments in disease prevention complements? The case of statins and health behaviors. (2014) (34)
Patients value metastatic cancer therapy more highly than is typically shown through traditional estimates. (2012) (34)
Aging and the Growth of Long-Term Care (1999) (32)
Quality-adjusted cost of care: a meaningful way to measure growth in innovation cost versus the value of health gains. (2015) (32)
THE FISCAL CONSEQUENCES OF TRENDS IN POPULATION HEALTH (2010) (32)
Social Insurance and the Design of Innovation Incentives (2004) (31)
The benefits from giving makers of conventional 'small molecule' drugs longer exclusivity over clinical trial data. (2011) (31)
The value of medical and pharmaceutical interventions for reducing obesity. (2012) (31)
Insurers’ Negotiating Leverage and the External Effects of Medicare Part D (2010) (30)
A Stock-Flow Analysis of the Welfare Caseload (2004) (29)
Is nursing home demand affected by the decline in age difference between spouses (2003) (28)
Real‐world resource use and costs of haemophilia A‐related bleeding (2017) (27)
Annual Expenditures for Nursing Home Care: Private and Public Payer Price Growth, 1977 to 2004 (2009) (27)
Time-Inconsistency and Welfare (2004) (26)
Impact of oral nutrition supplements on hospital outcomes in pediatric patients. (2014) (25)
Economic Burden of Disease-Associated Malnutrition in China (2015) (24)
Prescription Drug Advertising and Drug Utilization: The Role of Medicare Part D (2014) (24)
Health technology assessment with risk aversion in health. (2020) (24)
Formulary restrictions on atypical antipsychotics: impact on costs for patients with schizophrenia and bipolar disorder in Medicaid. (2014) (24)
Value of expanding HCV screening and treatment policies in the United States. (2016) (23)
Burden, timing, and relationship of cardiovascular hospitalization to mortality among Medicare beneficiaries with newly diagnosed atrial fibrillation. (2013) (23)
Does Intellectual Property Restrict Output? An Analysis of Pharmaceutical Markets (2012) (23)
Medical professional liability risk among US cardiologists. (2014) (22)
Health Technology Assessment With Diminishing Returns to Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach. (2021) (21)
The Contributions of Improved Therapy and Earlier Detection to Cancer Survival Gains, 1988-2000 (2010) (21)
The Value of Diagnostic Testing in Personalized Medicine (2013) (20)
Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer. (2015) (19)
Pharmaceutical advertising and Medicare Part D. (2013) (19)
Intellectual Property and Marketing (2006) (19)
Chronic Disease and Trends in Severe Disability in Working Age Populations (2008) (18)
Innovative Contracting for Pharmaceuticals and Medicaid's Best-Price Rule. (2018) (18)
Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes? (2019) (18)
Economics of Obesity (2006) (17)
A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis (2019) (17)
Defense costs of medical malpractice claims. (2012) (16)
Medication adherence and measures of health plan quality. (2015) (16)
Access to credible information on schizophrenia patients’ medication adherence by prescribers can change their treatment strategies: evidence from an online survey of providers (2017) (16)
Value of survival gains in chronic myeloid leukemia. (2012) (15)
The Labor Market Value of Health Improvements (2006) (15)
Are the young becoming more disabled?: Rates of disability appear to be on the rise among people ages eighteen to fifty-nine, fueled by a growing obesity epidemic (2004) (15)
Understanding the Economic Consequences of Shifting Trends in Population Health (2009) (15)
Mortality Risk, Insurance, and the Value of Life (2018) (14)
Issues and Options for Government Intervention in the Market for Terrorism Insurance (2003) (14)
The economics of integrating injury and illness prevention and health promotion programs: (585772012-004) (2012) (13)
The Welfare Effects of Public Drug Insurance (2007) (13)
GETTING AMERICANS BACK TO WORK (AND SCHOOL) WITH POOLED TESTING (2020) (12)
The Relationship between Commercial Health Care Prices and Medicare Spending and Utilization. (2015) (12)
The determinants of recent gains in cancer survival: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database (2008) (11)
Insurance and Innovation in Health Care Markets (2005) (11)
Coverage and use of cancer therapies in the treatment of chronic myeloid leukemia. (2012) (11)
The Effect of Regulation on Pharmaceutical Revenues (2009) (11)
Estimating the Value of New Technologies That Provide More Accurate Drug Adherence Information to Providers for Their Patients with Schizophrenia. (2016) (11)
The impact of insulin type on severe hypoglycaemia events requiring inpatient and emergency department care in patients with type 2 diabetes. (2013) (10)
Predicting quantity and quality of life with the Future Elderly Model. (2020) (10)
The Value of Progression-Free Survival in Metastatic Breast Cancer: Results From a Survey of Patients and Providers (2019) (10)
Intellectual Property, Information Technology, Biomedical Research, and Marketing of Patented Products (2011) (10)
Insurer Bargaining and Negotiated Drug Prices in Medicare Part D (2009) (9)
Future Health and Medical Care Spending of the Elderly (2005) (9)
The role of imperfect surrogate endpoint information in drug approval and reimbursement decisions. (2017) (9)
The wider public health value of HCV treatment accrued by liver transplant recipients. (2016) (9)
Healing the Poor: The Influence of Patient Socioeconomic Status on Physician Supply Responses (2016) (9)
Does knowledge of patient non-compliance change prescribing behavior in the real world? A claims-based analysis of patients with serious mental illness (2018) (8)
Effects of Expanding Health Screening on Treatment - What Should We Expect? What Can We Learn? (2018) (8)
The Economic Burden of Diabetic Macular Edema from a U.S. Private Payer Perspective (2011) (8)
The cost of adherence mismeasurement in serious mental illness: a claims-based analysis. (2017) (8)
Food Prices, Income, and Body Weight (2011) (8)
Can Oral Nutritional Supplements Improve Medicare Patient Outcomes in the Hospital? (2014) (8)
Annual Expenditures for Nursing Home Care (2009) (8)
The Trade-off Between Speed and Safety in Drug Approvals. (2017) (8)
Costs and spillover effects of private insurers' coverage of hepatitis C treatment. (2016) (8)
Medical Care Output and Productivity in the Nonprofit Sector (2001) (8)
Quantity Over Quality (2002) (8)
Medicaid prior authorization policies and imprisonment among patients with schizophrenia. (2014) (7)
Obesity and Disability (2004) (7)
CAR-T therapy and historical trends in effectiveness and cost-effectiveness of oncology treatments. (2020) (7)
Retirement and Weight (2008) (7)
Measuring the value of better diabetes management. (2013) (7)
Medication Adherence Patterns Among Patients with Multiple Serious Mental and Physical Illnesses (2018) (7)
Tort Liability and the Market for Prescription Drugs (2010) (7)
Measuring the COVID-19 Mortality Burden in the United States (2021) (6)
Careful use of science to advance the debate on the UK Cancer Drugs Fund. (2014) (6)
The value of surrogate endpoints for predicting real-world survival across five cancer types (2016) (6)
International Differences in Longevity and Health and Their Economic Consequences (2009) (6)
Estimating the Future Burden of Cardiovascular Disease in China and the Potential Value of Universal Lipid and Blood Pressure Control (2016) (6)
How Does Treating Chronic Hepatitis C Affect Individuals in Need of Organ Transplants in the United Kingdom? (2019) (6)
Association Between Spending and Outcomes for Patients With Cancer. (2019) (6)
Optimal Liability for Terrorism (2005) (6)
Can the ACA Improve Population Health? (2010) (6)
Quantifying Gains in the War on Cancer Due to Improved Treatment and Earlier Detection (2016) (6)
Incentives to Innovate (2012) (5)
Modeling the Health and Medical Care Spending of the Future Elderly (2008) (5)
A guide to extending and implementing generalized risk-adjusted cost-effectiveness (GRACE) (2021) (5)
A Cost-Benefit Analysis of Using Evidence of Effectiveness in Terms of Progression Free Survival in Making Reimbursement Decisions on New Cancer Therapies (2014) (5)
The economics of alternative payment models for pharmaceuticals (2021) (5)
Patient Outcomes and Cost Effects of Medicaid Formulary Restrictions on Antidepressants (2014) (5)
The Effect of Pharmaceutical Regulation on Revenues (2008) (5)
Adoption of Digital Health Technologies in the Practice of Behavioral Health: Qualitative Case Study of Glucose Monitoring Technology. (2021) (5)
Reconsidering the economic value of multiple sclerosis therapies. (2016) (5)
Technological Change and the Growth of Obesity: A Theoretical and Empirical Examination (2002) (5)
Early Delays in Insurance Coverage and Long-term Use of Home-based Peritoneal Dialysis (2020) (5)
The effect of functional status impairment on nursing home admission risk among patients with advanced Parkinson’s disease (2019) (4)
Temporal Trends in Mortality after Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Regression Analysis (2020) (4)
HIV Treatment Breakthroughs and Risky Sexual Behavior (2006) (4)
Using Information on Patient Adherence to Antipsychotic Medication to Understand Their Adherence to Other Medications. (2019) (4)
TEMPORAL TRENDS IN 30-DAY AND 1-YEAR MORTALITY RATES AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT: A SYSTEMATIC REVIEW AND META-REGRESSION ANALYSIS (2019) (4)
A response to the points by Manton and Williamson. (2003) (4)
Value of Reducing Wait Times for Chimeric Antigen Receptor T-Cell Treatment: Evidence From Randomized Controlled Trial Data on Tisagenlecleucel for Diffuse Large B-Cell Lymphoma. (2022) (4)
Clinical evidence inputs to comparative effectiveness research could impact the development of novel treatments. (2015) (4)
Evaluation of Medical Technologies with Uncertain Benefits (2019) (4)
Challenging Assumptions of Outcomes and Costs Comparing Peritoneal and Hemodialysis. (2021) (4)
Understanding price growth in the market for targeted oncology therapies. (2019) (3)
Crosswalk between the Mini‐Mental State Examination and the Telephone Interview for Cognitive Status (TICS‐27/30/40) (2022) (3)
Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials (2022) (3)
Unintended Consequences of Products Liability: Evidence from the Pharmaceutical Market (2014) (3)
Treating people right: Who goes untreated with systemic therapy for metastatic prostate cancer (mPC)? (2012) (3)
Cheap Food, Societal Norms, and the Economics of Obesity (2006) (3)
Regulating Drug Prices: U.S. Policy Alternatives in a Global Context (2008) (3)
Cost variation and savings opportunities in the Oncology Care Model. (2018) (3)
Saving Lives or Saving Money? Understanding the Dual Nature of Physician Preferences (2015) (3)
Preventing Obesity and Its Consequences: Highlights of RAND Health Research (2011) (3)
Unintended Consequences of Products Liability: Evidence from the Pharmaceutical Market (2014) (3)
Public-Private Partnership as a Path to Affordable Healthcare in Emerging Markets (2015) (3)
What do pharmaceuticals really cost in the long run? (2017) (3)
Prophylactic Defibrillators in Patients With Severe Chronic Kidney Disease (2016) (3)
1 Retirement and Weight (2008) (3)
Valuing Health Technologies at NICE (2010) (2)
Clinical Outcomes Associated With Rates of Sulfonylurea Use Among Physicians (2013) (2)
Understanding and improving value frameworks with real-world patient outcomes. (2018) (2)
Timing is everything: time to ADT and chemotherapy initiation for treatment of metastatic prostate cancer (2012) (2)
Public Financing and the Market for Long-Term Care (2001) (2)
P014 AVERAGE ANNUAL HEALTHCARE COSTS FOR PEDIATRIC AND ADULT PATIENTS WITH CROHN’S DISEASE OR ULCERATIVE COLITIS (2018) (2)
The Social Value of Improvement in Activities of Daily Living among the Advanced Parkinson’s Disease Population (2020) (2)
Greater Spending Associated with Improved Survival for Some Cancers in OCM-Defined Episodes. (2018) (2)
Are Biopharmaceutical Budget Caps Good Public Policy? (2016) (2)
The Complex Relationship between Healthcare Reform and Innovation (2015) (2)
The Economic Burden of Crohnʼs Disease and Ulcerative Colitis in the United States: A Lifetime Healthcare Cost Analysis: 2017 Presidential Poster Award: 715 (2017) (2)
How Does Health Insurance Affect Workers' Compensation Filing? (2005) (2)
The Total Direct Cost of Healthcare in the United States in Patients with Crohn's Disease and Ulcerative Colitis: An Age Specific Analysis (2017) (2)
Forecasting the nursing home population. Point and Counterpoint. Authors' reply (2003) (2)
Malpractice Risk, by Physician Specialty: (2011) (2)
Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018 (2021) (2)
Unintended Consequences of Products Liability: Evidence from the Pharmaceutical Market* (2020) (2)
Patents, innovation, and the welfare effects of Medicare Part D. (2010) (2)
Complications of Crohnʼs Disease and Ulcerative Colitis: Understanding the Lifetime Risks: 716 (2017) (2)
Share of Oncology Versus Nononcology Spending in Episodes Defined by the Centers for Medicare & Medicaid Services Oncology Care Model. (2018) (2)
Comparative effectiveness of antiarrhythmic drugs on cardiovascular hospitalization and mortality in atrial fibrillation. (2013) (2)
Want More Value from Prescription Drugs? We Need to Let Prices Rise and Fall (2013) (1)
Vaccine Allocation Priorities Using Disease Surveillance and Economic Data (2022) (1)
Does Medicare Benefit the Poor? Appendix (2005) (1)
Abstract 257: A Long-Term Comparison of Clinical and Economic Outcomes with Novel Oral Anti- Coagulants (2014) (1)
Chlorhexidine Rinse for Prevention of Urethritis in Men Linked to Oral Sex (2011) (1)
Reconsidering the Economic Value of Therapies for Multiple Sclerosis in the United States: Who Derives Benefit from Medical Technology? (2016) (1)
Time to ADT and chemotherapy initiation for treatment of metastatic prostate cancer (mPC). (2012) (1)
Does patient cost sharing for HCV drugs make sense? (2016) (1)
Comparative effectiveness research and formulary placement: the case of diabetes. (2013) (1)
A new method for determining patient payments for outpatient drugs. (2002) (1)
P319: The impact of oral nutritional supplementation in patients aged 65+ with COPD (2014) (1)
Corrigendum to "Health technology assessment with risk aversion in health" [J. Health Econ. 72 (2020) 102346]. (2021) (1)
Preventing Obesity and Its Consequences (2011) (1)
The Effect of Functional Status on Nursing Home Admission among Patients with Advanced Parkinson’s Disease (P1.024) (2016) (1)
Treating people right: Who goes untreated with systemic therapy for metastatic prostate cancer (mPC)? (2012) (1)
Time to ADT and chemotherapy initiation for treatment of metastatic prostate cancer (mPC). (2012) (1)
Impact of non‐binding FDA guidances on primary endpoint selection in Alzheimer's disease trials (2022) (1)
Malpractice Liability and Medical Costs (2007) (1)
The Benefits of Greater Data Exclusivity under the Hatch-Waxman Act (2009) (0)
Health Care Costs And Clinical Outcomes Associated With Rates Of Sulfonylurea Use By Physicians (2013) (0)
P0025 : The public health value of sparing livers for transplantation through systematic treatment of hepatitis C (2015) (0)
PIH24 Modeling the Health and Medical Care Spending of the Future Elderly: An Update Using the Future Elderly Model (2012) (0)
Value of Cancer Spending (2012) (0)
Correspondence regarding "A benefit-based copay for prescription drugs" [1] (multiple letters) (2002) (0)
RAND Corporation From the SelectedWorks of Darius N . Lakdawalla September , 2006 The Nonprofit Sector and Industry Performance (2017) (0)
HIV Treatment and Risky Sexual Behavior (2005) (0)
Terrorism Insurance Policy and the Public Good (2004) (0)
Patients’ Willingness To Pay: The Authors Reply (2012) (0)
Increased Lifetime Risk of Intestinal Complications and Extraintestinal Manifestations in Crohn's Disease and Ulcerative Colitis. (2022) (0)
The Impact Of Oral Nutritional Supplementation In Medicare Patients With Copd (2014) (0)
Improving Patient-Centered Care in Diabetes With Comparative Effectiveness Research (2013) (0)
PND37 PROJECTING THE BURDEN OF ALZHEIMER'S DISEASE AND EVALUATING THE POTENTIAL IMPACTS OF PREVENTING ALZHEIMER'S DISEASE IN THE UNITED STATES (2010) (0)
RAND Health Research Highlights: Malpractice Risk, by Physician Specialty (2012) (0)
Measuring the cost-effectiveness (CE) of therapies treating metastatic colorectal cancer (mCRC). (2011) (0)
ESTIMATING THE LIFETIME PRICE OF PHARMACEUTICALS: WHAT ARE THE LONG-TERM COSTS TO SOCIETY? (2016) (0)
Title Optimal Liability for Terrorism Permalink (2005) (0)
Impacts of First-in-Class Drug Approvals on Future in-Class Innovation (2021) (0)
MA14.09 Demonstrating Life Expectancy Gains with Immuno-Oncology (IO) Therapies (2017) (0)
Policy Options for European Pharmaceutical Markets (2018) (0)
Abstract 16196: The Economic Value of Statin Therapy (2011) (0)
Effect of Oral Nutritional Supplements On Hospital Outcomes in Patients Aged 65+ With Congestive Heart Failure. (2014) (0)
PCN169 - A FLEXIBLE OPEN-SOURCE COST-EFFECTIVENESS MODEL FOR METASTATIC EGFR+ NON-SMALL CELL LUNG CANCER (2018) (0)
CARDIOVASCULAR HOSPITALIZATION IS A STRONG PREDICTOR OF MORTALITY IN MEDICARE BENEFICIARIES WITH NEWLY DIAGNOSED ATRIAL FIBRILLATION (2012) (0)
Of High-Cost Cancer Therapies How Cancer Patients Value Hope And The Implications For Cost-Effectiveness Penrod and Tomas Philipson (2012) (0)
Reforming medicare's dialysis payment policies: implications for patients with secondary hyperparathyroidism. (2014) (0)
Freedom to innovate: the perils of centralized medical research. (2012) (0)
A NEW METHOD FOR COUNTING HEMOPHILIA-RELATED BLEEDING EVENTS IN CLAIMS DATA (2015) (0)
Are the Young Becoming More Disabled ? Appendix (2003) (0)
How well do surrogate endpoints and overall survival endpoints in clinical trials predict real-world survival? (2015) (0)
Regulating Drug Prices (2008) (0)
Adoption of Digital Health Technologies in the Practice of Behavioral Health: Qualitative Case Study of Glucose Monitoring Technology (Preprint) (2020) (0)
Two steps forward, one step back: 50 years of societal value from LDL-C-lowering therapies. (2021) (0)
Regional variation in survival after metastatic prostate cancer diagnosis (2012) (0)
EE354 Heterogeneity in the Economic Value of Early Alzheimer's Disease-Modifying Therapies: An Analysis of Patient Subgroups (2022) (0)
Preventing Complications of Central Venous Catheterization (2003) (0)
INTRODUCTION Medical innovation is frequently pinpointed as the primary driver for the rising cost of health insurance (2013) (0)
RAND Corporation From the SelectedWorks of Darius N . Lakdawalla September , 2006 Intellectual Property and Marketing (2017) (0)
An Economic Model of Surrogate Endpoints (2016) (0)
PCV22 LONG-TERM BENEFITS OF EXPANDED ACCESS TO VALVE REPLACEMENT FOR AORTIC STENOSIS PATIENTS (2020) (0)
The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Model for Measuring the Value of Gains in Health: An Exact Formulation (2023) (0)
12. The Complex Relationship between Healthcare Reform and Innovation - Darius Lakdawalla, Anup Malani, and Julian Reif (2015) (0)
Predicting real-world effectiveness using overall survival and progression-free survival-based clinical trial efficacy measures. (2016) (0)
PNS72 EVALUATION OF MEDICAL TECHNOLOGIES WITH UNCERTAIN BENEFITS (2019) (0)
Access to Disease-Modifying Alzheimer's Therapies: Addressing Possible Challenges Using Innovative Payment Models. (2022) (0)
Cost Versus The Value Of Health Gains Quality-Adjusted Cost Of Care : A Meaningful Way To Measure Growth In Innovation and (2015) (0)
QLIF-05. PATIENT PREFERENCES FOR GLIOBLASTOMA MULTIFORME: A DISCRETE CHOICE EXPERIMENT (2016) (0)
Measuring Value in Innovative Medicines (2016) (0)
Opportunity for all? Socioeconomic disparities in chemotherapy (CT) use for metastatic prostate cancer (mPC). (2012) (0)
Impact Of Comparative Effectiveness Research On Biomedical Innovation And Population Health (2013) (0)
Methods to Adjust Willingness to Pay (WTP) Measures for Severity of Illness. (2023) (0)
Abstract 227: Estimating the Value of Effective Lipid Management in China (2014) (0)
Hematologic Cancers More Costly and Have Fewer Savings Options Than Solid Tumors Under the OCM (2017) (0)
Health and Access Effects of New Drugs: Combining Experimental and Non-Experimental Data (2010) (0)
Regional variation in survival after metastatic prostate cancer diagnosis. (2012) (0)
Value of Survival Gains In Chronic Myelogenous Leukemia (2010) (0)
Abstract 146: Evolving Clinical Benefits and Social Value of Lipid Lowering Therapies (2019) (0)
Health, Body Weight, and Obesity (2016) (0)
Market Exclusivity For Drugs: The Authors Reply (2011) (0)
The Role of Specialty Drugs in Private Sector Healthcare Spending (2013) (0)
PCN167 - IMPROVEMENT OF AN OPEN-SOURCE COST-EFFECTIVENESS MODEL BASED ON PUBLIC FEEDBACK (2018) (0)
The Social Value of Immunotherapy in Non-Small Cell Lung Cancer (2016) (0)
1212 Improvements in progression-free survival and real-world cost: A study of treatments for five tumor sites (2015) (0)
Adherence Patterns Among Patients Using Oral Atypical Antipsychotics and Other Medications (2017) (0)
PCN92 THE WAR ON CANCER: AN ECONOMIC EVALUATION OF RECENT GAINS IN CANCER SURVIVAL (2008) (0)
The Economic Value of Medical Innovation (2012) (0)
Productivity in the Nonprofit Sector (2001) (0)
ST3 Development of a Survey-Based Predictive Model for Clinical Dementia Rating in Alzheimer's Disease (2021) (0)
Medical Care Costs of Patients with Amyotrophic Lateral Sclerosis in the Medicare Program (P07.065) (2013) (0)
Editors' Summary (2010) (0)
CAR-T Therapy Displays Favorable Gains in Health Outcomes and Competitive Cost-Effectiveness When Compared with Past Innovative Cancer Treatments (2018) (0)
WORKING PAPER SERIES INTELLECTUAL PROPERTY AND MARKETING (2006) (0)
Medicaid formulary restrictions and expenditures for patients with major depressive disorder (2014) (0)
PP128-SUN: The Impact of Oral Nutritional Supplementation in Medicare Patients with COPD (2014) (0)

This paper list is powered by the following services:

Other Resources About Darius Lakdawalla

What Schools Are Affiliated With Darius Lakdawalla?

Darius Lakdawalla is affiliated with the following schools:

Darius Lakdawalla's Academic­Influence.com Rankings